Non-invasive Brain Stimulation for Treating Symptomatic Convergence Insufficiency

NCT ID: NCT05877560

Last Updated: 2024-12-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this randomized controlled trial is to test the effectiveness of non-invasive brain stimulation in treating adults with symptomatic convergence insufficiency compared to vergence/accommodative therapy. The main questions it aims to answer are:

1. Can non-invasive brain stimulation shorten the treatment time of office-based vergence/accommodative therapy for convergence insufficiency?
2. Is non-invasive brain stimulation alone just as effective as office-based vergence/accommodative therapy in treating convergence insufficiency?

The investigators hypothesize that non-invasive brain stimulation will shorten the treatment time from 12 weeks to 8 weeks of office-based vergence/accommodative therapy and that non-invasive brain stimulation alone would be equally effective as office-based vergence/accommodative therapy in improving symptomatic convergence insufficiency.

Participants will be randomized into one of three treatment groups:

1. Non-invasive brain stimulation with office-based vergence/accommodative therapy.
2. Sham stimulation with office-based vergence/accommodative therapy.
3. Non-invasive brain stimulation only.

Researchers will compare baseline measurements of near point of convergence (NPC) and positive fusional vergence (PFV) to post-treatment measurements for each group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Convergence Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NIBS-OBVAT

8 sessions of non-invasive brain stimulation with 8 weeks of office-based vergence/accommodative therapy.

Group Type ACTIVE_COMPARATOR

Anodal-Transcranial Direct Current Stimulation

Intervention Type DEVICE

Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.

Office-Based Vergence/Accommodative Therapy

Intervention Type BEHAVIORAL

Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.

NIBS

8 sessions of non-invasive brain stimulation only.

Group Type ACTIVE_COMPARATOR

Anodal-Transcranial Direct Current Stimulation

Intervention Type DEVICE

Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.

OBVAT

8 sessions of sham stimulation with 8 weeks of office-based vergence/accommodative therapy.

Group Type SHAM_COMPARATOR

Office-Based Vergence/Accommodative Therapy

Intervention Type BEHAVIORAL

Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.

Sham Transcranial Direct Current Stimulation

Intervention Type DEVICE

Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anodal-Transcranial Direct Current Stimulation

Non-invasive brain stimulation will involve the use of anodal transcranial direct current stimulation to apply a 2 milliamp current over the left frontal eye field for approximately 20 minutes with a ramp up to the maximum programmed current and ramp down of 20 seconds.

Intervention Type DEVICE

Office-Based Vergence/Accommodative Therapy

Office-based vergence accommodative therapy involves weekly in-office appointments with the therapist lasting approximately 60 minutes per visit during which time in-office procedures will be performed, and home therapy procedures will be demonstrated. Participants will be prescribed 15 minutes of home reinforcement therapy procedures to be completed 5 days per week. Therapy will consist of two phases adapted from the Convergence Insufficiency Treatment Trial (CITT). Therapy procedures will include gross convergence, accommodation. non-computer based vergence, and computer-based vergence.

Intervention Type BEHAVIORAL

Sham Transcranial Direct Current Stimulation

Sham transcranial direct current stimulation will be applied over the left frontal eye field with the current ramping up for 20 seconds before ramping down for 20 seconds. The 2 milliamp current stimulation will occur for only a few seconds at the start and at the end of the 20 minutes.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

tDCS a-tDCS OBVAT Orthoptic training Sham tDCS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Best-corrected visual acuity of \> 20/25 in each eye at distance and near
* Exophoria at near at least 4∆ greater than at far
* Receded near point of convergence of \> 6 cm break
* Insufficient positive fusional vergence at near (\< 15∆ base-out blur or break)
* CISS score of 16 and greater for children or 21 and greater for adults
* Have had a dilated fundus examination within the last 12 months
* Informed consent and willingness to participate in the study and be randomized

Exclusion Criteria

* Previously treated for convergence insufficiency with home- or office-based vergence/accommodative therapy
* Amblyopia (\> 2-line difference in best-corrected visual acuity between the two eyes)
* Constant strabismus
* History of strabismus surgery
* Convergence insufficiency secondary to acquired brain injury or neurological disorder
* Manifest or latent nystagmus
* Systemic disease known to affect accommodation, vergence, and ocular motility including multiple sclerosis, Graves disease, myasthenia gravis, Parkinson's disease, cerebral palsy, and diabetes
* Developmental disability, attention deficit hyperactivity disorder (ADHD), learning disability or cognitive dysfunction that would interfere with treatment
* Taking medications that can affect normal neurological function including antipsychotics, antiepileptics, and opioids
* Presence of metal or electronic implants in or on the body, including pacemakers
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Midwestern University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Arijit Chakraborty

Assistant Director of Research

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Midwestern University Eye Institute

Downers Grove, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Arijit Chakraborty, PhD

Role: CONTACT

630-960-3172

Adrienne C Quan, OD

Role: CONTACT

630-960-3183

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherri Olsen

Role: primary

1-630-515-7368

Arijit Chakraborty, PhD

Role: backup

Adrienne C Quan, OD

Role: backup

Clinton R Prestwich, OD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Duval JL, Jaubert D, Poizot-Martin I, De Jaureguiberry JP, Lafeuillade A, Giovannini M, Carloz E, Dhiver C, Gastaut JA. [Colonic leishmaniasis in AIDS]. Ann Med Interne (Paris). 1994;145(3):198-9. No abstract available. French.

Reference Type BACKGROUND
PMID: 8092638 (View on PubMed)

Xie Y, Wan B, Li W. [Effect of bee pollen on maternal nutrition and fetal growth]. Hua Xi Yi Ke Da Xue Xue Bao. 1994 Dec;25(4):434-7. Chinese.

Reference Type BACKGROUND
PMID: 7744390 (View on PubMed)

Nakano H, Ida T, Harada A, Horiba K, Sakakibara T, Kawase M, Tatsuno K, Obunai Y, Murata M. [Application of epicardial approach technique to the anterior-paraseptal type Wolff-Parkinson-White syndrome]. Kyobu Geka. 1989 May;42(5):358-62. Japanese.

Reference Type BACKGROUND
PMID: 2779032 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIRB-IL 22013

Identifier Type: -

Identifier Source: org_study_id